The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Haploidentical vs MUD transplantation in patients with lymphoma using PTCy
Alberto Mussetti, MD, The Catalan Institute of Oncology, Barcelona, Spain, comments on the findings of a retrospective study comparing the outcomes of patients with lymphoma who have received haploidentical vs matched unrelated donor (MUD) transplantation with post-transplant cyclophosphamide (PTCy). Overall, the study reported that patients who received a MUD transplant had a significantly better overall survival (OS), progression-free survival (PFS), as well as a better non-relapse mortality (NRM), and a lower incidence of acute and chronic graft-versus-host disease (GvHD). However, there were no differences in the relapse rate between the two cohorts. A sensitivity analysis was performed to address any bias caused by differences between the two study cohorts. Nevertheless, results should still be validated in a randomized prospective study. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
